



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. P63132US0

In re application of: Wolf-Georg FORSSMANN

Application No. 09/171,607

Art Unit: 1644

Filed: November 4, 1998

Examiner: Amy M. Decloux

For: BIOLOGICALLY ACTIVE PROTEIN (COLLAGEN FRAGMENT HF-COLL-18/514cf) FOR INHIBITING THE GROWTH OF TUMORS AND CAPILLARY PROLIFERATIONS

TRANSMITTAL

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RECEIVED

JUN 26 2003

Sir:

TECH CENTER 1600/2900

Transmitted herewith please find:

- ☒ response under Rule 821(g), including PTO Notice (copy), Sequence Listing, CRF, and Amendment entering Sequence Listing.
- ☒ Amendment
- ☒ Petition for extension of time
- ☒ Fee payment      ☒ A check for \$ 55 is attached.
- ☐ Charge \$ \* to Deposit Account No. 06-1358.

Fee Calculation					
Excess Claims					
	Nº of Claims	Highest Nº Paid For	Excess Claims	Small Entity Fee	Large Entity Fee
Total	*	⊖ * =	0	⊗ \$9 = \$	⊗ \$18 = \$
Ind.	*	⊖ * =	0	⊗ \$42 = \$	⊗ \$84 = \$
[ ] Multiple Dependent Claims (1 <sup>st</sup> Filing)				⊕ \$140 =	⊕ \$280 = \$
Excess Claims Fee				\$	\$
Extension of Time Fee				\$55	\$
Other:				\$	\$
Total Fee Due				\$55	\$0

- ☒ If a petition for extension of time is necessary, but not enclosed, then this acts as the petition. Charge any fees additionally necessary in connection herewith to Deposit Account No. 06-1358.


JACOBSON HOLMAN PLLC  
400 Seventh Street, N. W.  
Washington, D.C. 20004-2201  
Tel. (202) 638-6666  
Fax (202) 393-5350  
Date: June 24, 2003

By

William E. Player  
Registration No. 31,409

R:\rthomas\2003\JUNE\p63132us0 - transmittal-response-amd.wpd

RECEIVED  
JUN 26 2003  
TECH CENTER 1600/2900



Application No.: 09/171,607

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: Page 3 and Page 10 of the specification disclose sequences which lack SEQ ID NO: tags. See attached Office Action.

**Applicant Must Provide: ONLY IF THE CRF/PAPR COPY SEQUENCE LISTING DOES NOT CONTAIN SAID SEQUENCES.**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

**COPY**

**RECEIVED**  
JUN 26 2003  
TECH CENTER 1600/295



Attorney Docket No. P63132US0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Wolf-Georg FORSSMANN

Application No. 09/171,607

Art Unit: 1644

Filed: November 4, 1998

Examiner: Amy M. Decloux

For: BIOLOGICALLY ACTIVE PROTEIN (COLLAGEN FRAGMENT HF-COLL-18/514cf) FOR INHIBITING THE GROWTH OF TUMORS AND CAPILLARY PROLIFERATIONS

RESPONSE UNDER 37 CFR 1.821(g)

RECEIVED

Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

JUN 26 2003

TECH CENTER 1600/2900

Sir:

In accordance with the PTO notice in connection 37 CFR 1.182(g), a copy of which notice is attached, hereto, submitted herewith are:

- 1) computer readable form (CRF) of the Sequence Listing;
- 2) paper copy of the Sequence Listing; and
- 3) amendment entering the Sequence Listing.

The content of the CRF and the paper copy are the same and includes no new matter.

Favorable action is requested.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By

William E. Player  
Registration No. 31,409

400 Seventh Street, N.W.  
Washington, D.C. 20004  
Tel: (202) 638-6666  
Fax: (202) 393-5350  
Date: June 24, 2003  
WEP/

R:\thomas\2003\JUNE\p63132us0 - transmittal-response-amd.wpd